MEF2 and the Right Ventricle: From Development to Disease

Area of Science:

• Cardiovascular Physiology
• Molecular Biology
• Pulmonary Hypertension Research

Background:

• Pulmonary arterial hypertension (PAH) is a severe disease impacting survival, primarily through right ventricular dysfunction.
• The right ventricle (RV) is less understood than the left ventricle due to distinct developmental and structural properties.
• Understanding RV adaptation and dysfunction in PAH is critical for improving patient outcomes.

Purpose of the Study:

• To elucidate the role of myocyte enhancer factor 2 (MEF2) transcription factors in normal RV physiology.
• To investigate the involvement of MEF2 in RV response to increased afterload characteristic of PAH.
• To examine the contribution of MEF2 to endothelial dysfunction in PAH and identify potential therapeutic strategies.

Main Methods:

• Review of existing literature on RV function in normal physiology and PAH.
• Analysis of the role of MEF2 transcription factors in RV development and disease.
• Exploration of MEF2's involvement in RV adaptation to pressure overload.
• Investigation of MEF2's impact on pulmonary vasculature and endothelial cells in PAH.

Main Results:

• MEF2 transcription factors play a significant role in RV development and adaptation to stress.
• Dysregulation of MEF2 pathways contributes to RV hypertrophy and dysfunction in PAH.
• MEF2 influences endothelial cell function, exacerbating pulmonary vascular remodeling in PAH.

Conclusions:

• MEF2 transcription factors are key regulators of right ventricular function and maladaptation in pulmonary arterial hypertension.
• Targeting MEF2-mediated pathways presents a promising therapeutic avenue for PAH.
• Further research into MEF2's specific molecular mechanisms can guide novel treatment development for PAH.